Orchestra BioMed [OBIO] vs Voyager Therapeutics [VYGR] Detailed Stock Comparison

Orchestra BioMed Holdings, Inc.

NASDAQ
Loading...

Voyager Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Orchestra BioMed Holdings, Inc. wins in 8 metrics, Voyager Therapeutics Inc. wins in 9 metrics, with 0 ties. Voyager Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Orchestra BioMed Holdings, Inc. Voyager Therapeutics Inc. Better
P/E Ratio (TTM) N/A 6.07 N/A
Price-to-Book Ratio 4.48 1.22 Voyager Therapeutics Inc.
Debt-to-Equity Ratio 25.17 18.61 Voyager Therapeutics Inc.
PEG Ratio -2.47 -0.30 Voyager Therapeutics Inc.
EV/EBITDA -3.22 -0.65 Voyager Therapeutics Inc.
Profit Margin (TTM) -157.40% -296.53% Orchestra BioMed Holdings, Inc.
Operating Margin (TTM) 21.85% -172.35% Orchestra BioMed Holdings, Inc.
EBITDA Margin (TTM) 21.85% N/A N/A
Return on Equity -109.41% -48.29% Voyager Therapeutics Inc.
Return on Assets (TTM) -33.90% -24.86% Voyager Therapeutics Inc.
Free Cash Flow (TTM) $-49.45M $-135.06M Orchestra BioMed Holdings, Inc.
1-Year Return 37.19% 41.24% Voyager Therapeutics Inc.
Price-to-Sales Ratio (TTM) 7.36 5.96 Voyager Therapeutics Inc.
Enterprise Value $165.62M $80.83M Orchestra BioMed Holdings, Inc.
EV/Revenue Ratio 4.95 2.00 Voyager Therapeutics Inc.
Gross Profit Margin (TTM) 99.84% N/A N/A
Revenue per Share (TTM) $1 $1 Orchestra BioMed Holdings, Inc.
Earnings per Share (Diluted) $-1.11 $-2.04 Orchestra BioMed Holdings, Inc.
Beta (Stock Volatility) 0.60 1.38 Orchestra BioMed Holdings, Inc.
Short % of Float 2.46% 6.49% Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. vs Voyager Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

OBIO
VYGR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Orchestra BioMed Holdings, Inc.-1.28%-1.76%-2.99%-10.96%-18.24%-9.51%
Voyager Therapeutics Inc.0.28%-6.27%-7.47%-13.49%-4.77%-10.92%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Orchestra BioMed Holdings, Inc.37.19%-75.14%-61.44%-51.73%-51.73%-51.73%
Voyager Therapeutics Inc.41.24%-65.93%-8.08%-71.12%-78.62%-78.62%

Performance & Financial Health Analysis: Orchestra BioMed Holdings, Inc. vs Voyager Therapeutics Inc.

MetricOBIOVYGR
Market Information
Market Cap i$242.86M$240.78M
Market Cap CategoryMicro capMicro cap
10 Day Avg. Volume i133,035547,491
90 Day Avg. Volume i183,128648,930
Last Close$3.86$3.60
52 Week Range$2.20 - $5.42$2.83 - $5.55
% from 52W High-28.83%-35.14%
All-Time High$23.39 (Apr 03, 2023)$31.91 (Mar 05, 2018)
% from All-Time High-83.50%-88.72%
Growth Metrics
Quarterly Revenue Growth121.20%1.44%
Quarterly Earnings Growth121.20%1.44%
Financial Health
Profit Margin (TTM) i-1.57%-2.97%
Operating Margin (TTM) i0.22%-1.72%
Return on Equity (TTM) i-1.09%-0.48%
Debt to Equity (MRQ) i25.1718.61
Cash & Liquidity
Book Value per Share (MRQ)$0.94$3.32
Cash per Share (MRQ)$1.82$3.30
Operating Cash Flow (TTM) i$-48,963,000$-132,467,000
Levered Free Cash Flow (TTM) i$-20,247,876$-83,939,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Orchestra BioMed Holdings, Inc. vs Voyager Therapeutics Inc.

MetricOBIO (Apr 24, 2026)VYGR (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A6.07
Forward P/E i-2.47-2.36
PEG Ratio i-2.47-0.30
Price to Sales (TTM) i7.365.96
Price to Book (MRQ) i4.481.22
Market Capitalization
Market Capitalization i$242.86M$240.78M
Enterprise Value i$165.62M$80.83M
Enterprise Value Metrics
Enterprise to Revenue i4.952.00
Enterprise to EBITDA i-3.22-0.65
Risk & Other Metrics
Beta i0.601.38
Book Value per Share (MRQ) i$0.94$3.32

Financial Statements Comparison: Orchestra BioMed Holdings, Inc. vs Voyager Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricOBIO (2025)VYGR (2025)
Revenue/Sales i33.48M40.37M
Cost of Goods Sold i190,000N/A
COGS % of Revenue i0.6%0.0%
Gross Profit i33.29MN/A
Gross Margin i99.4%0.0%
Research & Development i58.19M134.67M
Operating Income (EBIT) i-51.81M-131.84M
Operating Margin i-154.7%-326.6%
EBITDA i-51.48M-127.78M
EBITDA Margin i-153.8%-316.5%
Pre-Tax Income i-52.70M-119.58M
Pre-Tax Income % of Revenue i-157.4%-296.2%
Income Tax iN/A144,000
Income Tax % of Revenue i0.0%0.4%
Net Income (Profit) i-52.70M-119.72M
Profit Margin i-157.4%-296.5%

Balance Sheet & Liquidity Metrics

MetricOBIO (2025)VYGR (2025)
Cash & Equivalents i34.69M65.30M
Total Current Assets i107.91M202.69M
Total Current Assets % of Revenue i322.3%502.0%
Total Current Liabilities i16.74M26.54M
Total Current Liabilities % of Revenue i50.0%65.7%
Long-Term Debt i15.20M28.66M
Long-Term Debt % of Revenue i45.4%71.0%
Total Shareholders Equity i53.57M196.08M
Retained Earnings i-362.58M-445.91M
Retained Earnings % of Revenue i-1,082.9%-1,104.4%
Property, Plant & Equipment i4.24M51.48M

Cash Flow Statement Comparison

MetricOBIO (2025)VYGR (2025)
Operating Cash Flow i-54.46M-130.75M
Operating Cash Flow % of Revenue i-162.6%-323.9%
Capital Expenditures i-489,000-2.60M
Free Cash Flow i-49.45M-135.06M
FCF Margin i-147.7%-334.5%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricOBIOVYGR
Shares Short i957,9393.29M
Short Ratio i3.913.56
Short % of Float i2.46%6.49%
Shares Outstanding i57.03M59.05M
Float Shares i32.49M38.95M
% Held by Insiders i27.92%15.35%
% Held by Institutions i38.23%60.06%
% Held by Public i33.85%24.59%

Dividend Analysis & Yield Comparison: Orchestra BioMed Holdings, Inc. vs Voyager Therapeutics Inc.

MetricOBIOVYGR
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A